Physician profile
Elizabeth D Deck
NPI 1396715546
$2,031.58
in general payments reported to CMS, 2019-2025
24 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.08 · 2022: $78.11 · 2023: $347 · 2024: $796 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $434.06 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $243.94 | 2024-2025 | Farxiga, Lokelma, Airsupra |
| Abbvie INC. | $240.18 | 2023-2025 | |
| Dexcom, INC. | $181.77 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $160.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $87.58 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $73.98 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.15 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.45 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $60.62 | 2023-2024 | Trintellix |
| Axsome Therapeutics, INC. | $52.57 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $47.84 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.78 | 2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $41.01 | 2024 | Voquezna |
| Jazz Pharmaceuticals INC. | $39.72 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.92 | 2025 | Otezla, Repatha |
| Inspire Medical Systems, INC. | $25.35 | 2024 | Inspire |
| Iovance Biotherapeutics, INC. | $24.10 | 2025 | Amtagvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.07 | 2025 | Jardiance |
| Phadia US INC. | $20.34 | 2025 | Immunocap |
| Aimmune Therapeutics, INC. | $19.96 | 2025 | Vowst |
| Glaxosmithkline, LLC. | $19.56 | 2022 | |
| Astellas Pharma US INC | $18.53 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $16.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Deck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.